Multiple Sclerosis and Related Disorders

The microbiota gut-brain axis: role in brain excitability and epilepsy 4:31
The microbiota gut-brain axis: role in brain excitability and epilepsy
Emilio Russo • 11 Aug 2021
Starting treatment in patients with a diagnosis of seizure disorder associated with MS 5:12
Starting treatment in patients with a diagnosis of seizure disorder associated with MS
Anca Arbune • 12 Aug 2021
Newly developed recommendations for palliative care in MS 5:46
Newly developed recommendations for palliative care in MS
Alessandra Solari • 29 Jun 2021
Updated guidelines for palliative care in advanced MS 2:56
Updated guidelines for palliative care in advanced MS
Alessandra Solari • 29 Jun 2021
Epidemiology and disease characteristics of late-onset MS 3:33
Epidemiology and disease characteristics of late-onset MS
Melinda Magyari • 29 Jun 2021
MicroRNA panel for multiple sclerosis: potential biomarkers? 1:12
MicroRNA panel for multiple sclerosis: potential biomarkers?
Bárbara Guerra Leal • 1 Jul 2021
Interleukin 1B in MS: analysis of a polymorphism in the gene promoter region 1:15
Interleukin 1B in MS: analysis of a polymorphism in the gene promoter region
Bárbara Guerra Leal • 1 Jul 2021
What does an MS diagnosis mean for patients today? 2:02
What does an MS diagnosis mean for patients today?
Giancarlo Comi • 21 Jun 2021
Work productivity improves in patients with RRMS treated with ocrelizumab 4:55
Work productivity improves in patients with RRMS treated with ocrelizumab
Giancarlo Comi • 21 Jun 2021
Why are B-cells such a valuable target in MS? 3:09
Why are B-cells such a valuable target in MS?
Giancarlo Comi • 21 Jun 2021
Real-world comparison of natalizumab exit strategies in patients with RRMS 9:25
Real-world comparison of natalizumab exit strategies in patients with RRMS
Aurora Zanghì • 22 Jun 2021
Next steps in MS treatment: optimizing what we have 3:36
Next steps in MS treatment: optimizing what we have
Giancarlo Comi • 21 Jun 2021
Benefits of SC natalizumab in MS 2:43
Benefits of SC natalizumab in MS
Bart Van Wijmeersch • 23 Jun 2021
Enhancing convenience and flexibility with SC natalizumab for MS 2:19
Enhancing convenience and flexibility with SC natalizumab for MS
Bart Van Wijmeersch • 23 Jun 2021
Managing disease progression: a challenge in MS care 5:13
Managing disease progression: a challenge in MS care
Bart Van Wijmeersch • 23 Jun 2021
Future challenges for MS research: progressive disease 2:12
Future challenges for MS research: progressive disease
Mar Tintoré • 7 Jun 2021
The content of VJNeurology is intended for healthcare professionals